Watch MIRM. Know when insiders buy.
One email the day a filing lands. Free.
Work order
44
WATCH · insiders 25, shorts 63
Insiders, 90 days
−$3M
net selling · 0 buys, 3 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.6BP/E —DIV YIELD —FCF YIELD -3.49%REV TTM $618.1M +44.0%NET INCOME −$860.2MNET CASH —52W 64.10 – 128.57SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $176.2M | +37.9% | — | −$42.5M | −$67.2M | — | -1.06 | −$44.3M | $23K | −$44.3M | Aug 5 |
| Q1 2026 · Mar 31 | $159.9M | +43.3% | — | −$789.5M | −$790.2M | — | -13.43 | −$228.8M | $664K | −$229.4M | Aug 5 |
| Q4 2025 · Dec 31derived | $148.9M | +49.8% | — | −$4.6M | −$5.7M | — | -0.12 | $6.1M | $600K | $5.5M | Feb 25 |
| Q3 2025 · Sep 30 | $133M | +47.2% | — | $2.6M | $2.9M | — | 0.05 | $39.7M | $187K | $39.5M | Nov 4 |
| Q2 2025 · Jun 30 | $127.8M | +64.1% | — | −$5M | −$5.9M | — | -0.12 | $12M | $126K | $11.9M | Aug 5 |
| Q1 2025 · Mar 31 | $111.6M | +61.2% | — | −$15.2M | −$14.7M | — | -0.30 | −$2M | $41K | −$2M | Aug 5 |
| Q4 2024 · Dec 31derived | $99.4M | +42.9% | — | −$24.2M | −$23.8M | — | -0.49 | −$5.1M | $20K | −$5.1M | Feb 25 |
| Q3 2024 · Sep 30 | $90.4M | +89.4% | — | −$12.7M | −$14.2M | — | -0.30 | $4M | $181K | $3.8M | Nov 4 |
| Q2 2024 · Jun 30 | $77.9M | — | — | −$24.2M | −$24.6M | — | -0.52 | −$3.8M | $779K | −$4.6M | Nov 4 |
| Q1 2024 · Mar 31 | $69.2M | — | — | −$26.5M | −$25.3M | — | -0.54 | $15.2M | $13K | $15.2M | Nov 4 |
| Q4 2023 · Dec 31derived | $69.6M | — | — | −$32.6M | −$35.7M | — | -0.72 | −$16.6M | $0 | −$16.6M | Feb 25 |
| Q3 2023 · Sep 30 | $47.7M | — | — | −$25.1M | −$23.6M | — | -0.57 | −$18.2M | $0 | −$18.2M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $521.3M | — | −$22.1M | −$23.4M | -4.5% | -0.47 | $55.8M | $954K | $54.9M | — | — |
| FY2024 · to Dec 31 | $336.9M | — | −$87.6M | −$87.9M | -26.1% | -1.85 | $10.3M | $993K | $9.3M | — | — |
| FY2023 · to Dec 31 | $186.4M | — | −$109.2M | −$163.4M | -87.7% | -4.00 | −$70.9M | $109K | −$71.1M | — | — |
| FY2022 · to Dec 31 | $77.1M | — | −$131.2M | −$135.7M | -176.0% | -4.02 | −$120.1M | $278K | −$120.4M | — | — |
| FY2021 · to Dec 31 | $19.1M | — | −$173.4M | −$84M | -438.9% | -2.77 | −$132.8M | $24K | −$132.8M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$104.3M | −$103.3M | — | -4.09 | −$89.1M | $225K | −$89.3M | — | — |
Every number comes from Mirum Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.